$0.47
+0.05 (+11.78%)
Open$0.44
Previous Close$0.42
Day High$0.48
Day Low$0.42
52W High$1.60
52W Low$0.34
Volume—
Avg Volume266.0K
Market Cap16.10M
P/E Ratio—
EPS$-0.23
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+6,919.4% upside
Current
$0.47
$0.47
Target
$32.64
$32.64
$20.70
$32.64 avg
$34.69
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.66M | 3.60M | 4.58M |
| Net Income | -8,733,718 | -7,722,120 | -1,151,647 |
| Profit Margin | -238.3% | -226.4% | -25.2% |
| EBITDA | -8,532,498 | -7,963,329 | -1,556,423 |
| Free Cash Flow | — | — | -1,101,967 |
| Rev Growth | +1.8% | +1.8% | +24.2% |
| Debt/Equity | 4.08 | 4.08 | 0.58 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |